Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DelveInsight has launched a new report on “Metastatic castrate-resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Metastatic castrate-resistant Prostate Cancer – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Metastatic castrate-resistant Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic castrate-resistant Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Metastatic castrate-resistant Prostate Cancer Market Report:

1. The total prevalent cases of prostate cancer in the 7MM were observed to be 6,742,385 cases in 2017 which is expected to grow during the study period (2017–2030). In total prevalent cases of the 7MM;  the US accounted for the highest number of cases which were 3,170,339 cases in 2017.  
2. The total cases of mCRPC in the 7MM were found to be 77,318 in 2017 which is expected to grow during the study period
3. In 2017, there were 33,897 cases of mCRPC in the United States, while in Germany these cases were 11,369 which accounted for second-highest cases in the total cases of mCRPC in the 7MM.
4. Japan accounted for 10,421 cases of mCRPC in 2017, which is approximately 13% of the total 7MM cases of mCRPC.

Key benefits of the report:

1. Metastatic Castrate-resistant Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Metastatic castrate-resistant Prostate Cancer Epidemiology and Metastatic castrate-resistant Prostate Cancer  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Metastatic castrate-resistant Prostate Cancer market report provides insights on the current and emerging therapies.
3. Metastatic Castrate-resistant Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Metastatic castrate-resistant Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic castrate-resistant Prostate Cancer market.

Metastatic Castrate-resistant Prostate Cancer Overview

Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones and is known as distant or metastatic prostate cancer.

Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With mCRPC, cancer no longer completely responds to treatments that lower testosterone and it is found in other parts of the body. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone.

Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer

Metastatic Castrate-resistant Prostate Cancer Market 

The dynamics of the Metastatic castrate-resistant Prostate Cancer market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as AstraZeneca, Bristol-Myers Squibb, Janssen Research & Development, Hinova Pharmaceuticals, Hoffmann-La Roche, Pfizer, Astellas Pharma, Clovis Oncology, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Metastatic castrate-resistant Prostate Cancer Market Landscape 

Metastatic Castrate-resistant Prostate Cancer Pipeline Therapies and Key Companies 

1. Niraparib: Janssen Research & Development
2. Talzenna: Pfizer/Astellas Pharma
3. Opdivo (nivolumab): Bristol-Myers Squibb
4. LAE001: Laekna Therapeutics
5. Ipatasertib (RG7440): Hoffmann-La Roche 
6. EPI-7386: ESSA Pharmaceuticals

Metastatic Castrate-resistant Prostate Cancer Market Drivers 

• Rising Geriatric Population and High Prevalence Rate of mCRPC
• Surge in Awareness Regarding the Treatment of mCRPC
• Increase in Demand for mCRPC
• Treatment Products

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Metastatic castrate-resistant Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic castrate-resistant Prostate Cancer Market Overview at a Glance

6. Metastatic castrate-resistant Prostate Cancer Disease Background and Overview

7. Metastatic castrate-resistant Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic castrate-resistant Prostate Cancer 

9. Metastatic castrate-resistant Prostate Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Metastatic castrate-resistant Prostate Cancer Emerging Therapies

12. Metastatic castrate-resistant Prostate Cancer Market Outlook

13. Country-Wise Metastatic castrate-resistant Prostate Cancer Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Metastatic castrate-resistant Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Metastatic Castrate-resistant Prostate Cancer Pipeline 

“Metastatic castrate-resistant Prostate Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic castrate-resistant Prostate Cancer market. A detailed picture of the Metastatic castrate-resistant Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic castrate-resistant Prostate Cancer treatment guidelines.

Metastatic Castrate-resistant Prostate Cancer Epidemiology

DelveInsight’s ‘Metastatic castrate-resistant Prostate Cancer  Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic castrate-resistant Prostate Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market